Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma. The treatment combination of Calquence ...
Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL. Among patients with previously untreated chronic lymphocytic leukemia ...
AstraZeneca's BTK inhibitor Calquence has become the first drug in the class to be approved by the US FDA as a treatment for adult patients with previously untreated mantle cell lymphoma (MCL ...
The latest approval allows Calquence use with bendamustine and rituximab for adults with newly diagnosed mantle cell lymphoma who are not eligible to undergo hematopoietic stem cell ...
AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that chief executive Pascal Soriot recently said could be a "blockbuster ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback